-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $118

Benzinga·02/26/2026 19:39:16
Listen to the news
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $120 to $118.